‘Good virus’ may help WVU researchers slow progression of incurable eye disorders


A team of researchers with the West Virginia School of Medicine are studying how a benign virus can make new treatments for eye diseases possible.

Viruses have a bad reputation for a good reason. But some viruses do not harm people. Some can even help them.

Researchers with the West Virginia School of Medicine are studying how a benign virus can make new treatments for eye diseases possible. They are exploring how to use engineered adeno-associated virus, or AAV, to compensate for missing protein or swap out genetic mutations that cause vision problems and replace them with DNA that works as it should.

“Eighty-five percent of Americans are seropositive for AAV. However, the virus has never been associated with any pathological effect,” said Wen Tao Deng—an assistant professor in the Department of Ophthalmology and Visual Sciences—who is leading the effort.

Virus as a vehicle

“We engineered the virus to use it as a vehicle to deliver the genes we are interested in,” she said in a statement. “We use it as a tool to actually benefit us. So, this is a good virus.”

The National Eye Institute has awarded the five-year project $1.9 million.

The project focuses on genetic mutations that affect specific photoreceptors in the eye, called L- and M-cones.

“When you lose your L and M-cones, basically you lose visual acuity; you lose your ability to read; you lose your color vision,” Deng said. “It severely, severely affects your daily function.”

Deng and her colleagues will use mouse models they have genetically modified to lose their L- and M-cones in a way that mimics the experience of humans who inherit this mutation.

The investigators will analyze—on a molecular level—the unique mechanisms that underlie the disease.

Trojan horse

They will take advantage of AAV’s “Trojan horse” ability to sneak into the nucleus of a photoreceptor and either replace its missing protein or rout a troublesome mutation while installing healthy DNA in its place.

Deng is also interested in developing new treatments that could delay the onset, or slow the progression, of a range of eye diseases—from red-green color vision defects (the most common form of color deficiency) to blue cone monochromacy (a much rarer condition) and other forms of cone dystrophy.

“We are also interested in delaying the degeneration,” Deng said. “Some patients gradually lose vision. So, if you could delay their photoreceptor cell degeneration for 5 to 10 years, this also could give them an expanded window of treatment. This is especially important for children to buy time until we identify a treatment to reverse it.”